Scholar Rock Holding

Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role. Scholar Rock applies its myostatin biology platform to advance treatments intended to address significant unmet medical needs in patients across pediatric and adult populations. The company is headquartered in Cambridge, Massachusetts, and its common stock is used by investors to track the market’s view of its clinical development progress, regulatory milestones, and broader biopharmaceutical execution.